123 related articles for article (PubMed ID: 20093295)
1. The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations.
Paulsson K; Haferlach C; Fonatsch C; Hagemeijer A; Andersen MK; Slovak ML; Johansson B;
Hum Mol Genet; 2010 Apr; 19(8):1507-14. PubMed ID: 20093295
[TBL] [Abstract][Full Text] [Related]
2. Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features.
Penther D; Etancelin P; Lusina D; Bidet A; Quilichini B; Gaillard B; Rafdord-Weiss I; Mozziconacci MJ; Ittel A; Roche-Lestienne C; Barin C; Soler G; Daudignon A; Nadal N; Chapiro E; Lefebvre C; Godon C; Nadeau G; Mugneret F; Richebourg S; Viailly PJ; Ferret Y; Nguyen-Khac F; Eclache V;
Am J Hematol; 2019 Nov; 94(11):E285-E288. PubMed ID: 31379011
[No Abstract] [Full Text] [Related]
3. Isodicentric (X)(q13) in haematological malignancies: presentation of five new cases, application of fluorescence in situ hybridization (FISH) and review of the literature.
Dierlamm J; Michaux L; Criel A; Wlodarska I; Zeller W; Louwagie A; Michaux JL; Mecucci C; Van den Berghe H
Br J Haematol; 1995 Dec; 91(4):885-91. PubMed ID: 8547134
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a highly complex region in Xq13 and mapping of three isodicentric breakpoints associated with preleukemia.
McDonell N; Ramser J; Francis F; Vinet MC; Rider S; Sudbrak R; Riesselman L; Yaspo ML; Reinhardt R; Monaco AP; Ross F; Kahn A; Kearney L; Buckle V; Chelly J
Genomics; 2000 Mar; 64(3):221-9. PubMed ID: 10756090
[TBL] [Abstract][Full Text] [Related]
5. Large inverted repeats within Xp11.2 are present at the breakpoints of isodicentric X chromosomes in Turner syndrome.
Scott SA; Cohen N; Brandt T; Warburton PE; Edelmann L
Hum Mol Genet; 2010 Sep; 19(17):3383-93. PubMed ID: 20570968
[TBL] [Abstract][Full Text] [Related]
6. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
7. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome.
Mohamedali AM; Smith AE; Gaken J; Lea NC; Mian SA; Westwood NB; Strupp C; Gattermann N; Germing U; Mufti GJ
J Clin Oncol; 2009 Aug; 27(24):4002-6. PubMed ID: 19528370
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
9. Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts.
Dewald GW; Brecher M; Travis LB; Stupca PJ
Cancer Genet Cytogenet; 1989 Oct; 42(2):173-85. PubMed ID: 2790752
[TBL] [Abstract][Full Text] [Related]
10. Loss of ABCB7 gene: pathogenesis of mitochondrial iron accumulation in erythroblasts in refractory anemia with ringed sideroblast with isodicentric (X)(q13).
Sato K; Torimoto Y; Hosoki T; Ikuta K; Takahashi H; Yamamoto M; Ito S; Okamura N; Ichiki K; Tanaka H; Shindo M; Hirai K; Mizukami Y; Otake T; Fujiya M; Sasaki K; Kohgo Y
Int J Hematol; 2011 Mar; 93(3):311-318. PubMed ID: 21380928
[TBL] [Abstract][Full Text] [Related]
11. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
12. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
13. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
[TBL] [Abstract][Full Text] [Related]
14. Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
[TBL] [Abstract][Full Text] [Related]
15. TET2 mutations in myelodysplasia and myeloid malignancies.
Mullighan CG
Nat Genet; 2009 Jul; 41(7):766-7. PubMed ID: 19557078
[TBL] [Abstract][Full Text] [Related]
16. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
Soura EN; Karikas GA
J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
[TBL] [Abstract][Full Text] [Related]
17. Invariant phenotype and molecular association of biallelic
Awada H; Nagata Y; Goyal A; Asad MF; Patel B; Hirsch CM; Kuzmanovic T; Guan Y; Przychodzen BP; Aly M; Adema V; Shen W; Williams L; Nazha A; Abazeed ME; Sekeres MA; Radivoyevitch T; Haferlach T; Jha BK; Visconte V; Maciejewski JP
Blood Adv; 2019 Feb; 3(3):339-349. PubMed ID: 30709865
[TBL] [Abstract][Full Text] [Related]
18. Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome.
Dambruoso I; Boni M; Rossi M; Zappasodi P; Calvello C; Zappatore R; Cavigliano PM; Giardini I; Rocca B; Caresana M; Astori C; Cazzola M; Castagnola C; Bernasconi P
Cancer Genet; 2012 Jun; 205(6):285-94. PubMed ID: 22749034
[TBL] [Abstract][Full Text] [Related]
19. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
20. Isodicentric X chromosomes involving the Xq13 breakpoint in myelodysplasia and acute nonlymphocytic leukemia.
Mackinnon WB; Michael PM; Webber LM; Garson OM
Cancer Genet Cytogenet; 1988 Jan; 30(1):43-52. PubMed ID: 3422047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
